Obesity Drug Discoveries: what the future holds

Pharma Business Daily
Claim your FREE trial subscription!

Pharmaceutical:

Obesity Drug Discoveries: what the future holds

Espicom Business Intelligence
Management Report August 2007

eaknesses for current therapy approaches?
Which research approach is likely to achieve best clinical and commercial results and when are the resulting drugs likely to reach the market?
What are the development and regulatory challenges companies must overcome? The answers to these and many other questions can be found in this new 120+ page strategic management report Obesity Drug Discoveries: What the future holds (published August 2007). In addition, for those needing to monitor this developing area there is the Obesity Tracker, an online news service available for customers buying the web edition of the report.
The race is on among competing research strategies.
Obesity offers pharmaceutical companies a marketplace characterised by rapid and continuing growth, long-term unmet clinical need and a wide prevalence profile. The recognition of obesity as a serious global issue is relatively recent, and rising concern and interest has outpaced the industry’s ability to nurture products through the lengthy regulatory process.

Health payers will have to balance the cost of obesity treatment with the very real health benefits of reducing related conditions, such as diabetes and cardiovascular disease. With pressure to contain rising drug costs, arguments about paying for this “lifestyle” illness are bound to rage.

Furthermore, patient demand for drug-based intervention, even for those with a questionable clinical need, could significantly boost the market value.

Although 25 companies have products in clinical development, much interest lies in the research and prospects of big pharma companies such as GSK, sanofi-aventis, Merck & Co and Pfizer. However, in such a fledgling market, the opportunities for innovation to win through are better than in established and more exploited therapy areas.

UNIQUE COMPETITIVE ASSESSMENT SCORE
For each product reviewed, the report provides a critical competitor ratio analysis, based on our assessment of the following five criteria:
novelty/rationale for mechanism of action;
proof of concept/clinical data;
management expertise;
competition within the marketplace; and, risks associated with drug development in the therapeutic class.
Products analysed and their developers
Product
Developer
869682
GSK
AVE1625
sanofi-aventis
cetilistat
Alizyme/Takeda
Contrave
OREXIGEN Therapeutics
CP-945,598
Pfizer
Empatic
OREXIGEN Therapeutics
KRP-204
Kyorin
liraglutide
Novo Nordisk
lorcaserin
Arena Pharmaceuticals
OBE101
OBEcure
obinepitide
7TM Pharma
pramlintide
Amylin Pharmaceuticals
pramlintide combination therapies
Amylin Pharmaceuticals
PYY3-36
Nastech Pharmaceutical
Qnexa
VIVUS
S-2367
Shionogi
SLV319
Solvay/BMS
taranabant
Merck & Co
tesofensine
NeuroSearch

Number of pages - 1834

For full details, please email keithw@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.